Randomized trial · people
Exenatide: 29.2% spontaneous pregnancy vs 14.7% on metformin in PCOS
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In this trial, a short course of exenatide before conception led to more natural pregnancies than metformin in women with PCOS and excess weight, but total pregnancy rates after ART ended up similar.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 160
- Published
- 2022
- Journal
- Arch Gynecol Obstet
What they tested
Does 12 weeks of exenatide before trying to conceive lead to more pregnancies than metformin in women with PCOS who carry excess weight and have trouble getting pregnant?
How the study was done
A randomized trial with long-term follow-up in 160 overweight or obese, infertile Chinese women with PCOS (polycystic ovary syndrome), who took exenatide or metformin for 12 weeks and then all switched to metformin alone. Those not pregnant on their own during the second 12 weeks could be offered assisted reproductive technology (ART, medical help to conceive) up to week 64.

Model. Individual results vary.
What they found
By week 24, 29.2% of women in the exenatide group had become pregnant on their own, compared with 14.7% in the metformin group (p = 0.03). By week 64, counting pregnancies after ART too, the totals were similar: 79.2% with exenatide and 76% with metformin (p = 0.65). Pregnancy outcomes did not differ significantly between the groups. In both groups, natural pregnancy was linked to more weight loss and a better HOMA-IR score (a measure of insulin resistance).
What it doesn’t show
Exenatide was given for only 12 weeks, and the study included only Chinese women with PCOS and excess weight. The links with weight loss and insulin resistance come from a statistical model, not a direct test of cause.
The paper
Li et al. Effect of metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertility PCOS women: long-term follow-up of an RCT. Arch Gynecol Obstet. 2022.
The compound
More studies on Exenatide
- Exenatide: no cognitive benefit in mild cognitive impairmentRandomized trial · people · 2024
- Exenatide: lower intracranial pressure in IIH over 12 weeksRandomized trial · people · 2023
- Exenatide did not cut heavy drinking days in alcohol use disorderRandomized trial · people · 2022
- Exenatide plus dapagliflozin: UACR fell 39.6% vs 11.0% on placeboRandomized trial · people · 2021
- Exenatide, alone or with dapagliflozin, improved blood sugar in PCOSRandomized trial · people · 2021
- Exenatide ER: 0.9% HbA1c drop vs 1.5% with semaglutide in SUSTAIN 3Randomized trial · people · 2018
- Every study on Exenatide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.